<DOC>
	<DOCNO>NCT02181478</DOCNO>
	<brief_summary>This clinical trial study intra-osseous donor umbilical cord blood mesenchymal stromal cell co-transplant treating patient hematologic malignancy . Giving low dos chemotherapy total-body irradiation co-transplant donor umbilical cord blood mesenchymal stromal cell bone ( intra-osseous ) help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil time transplant may stop happening .</brief_summary>
	<brief_title>Intra-Osseous Co-Transplant UCB hMSC</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate feasibility combine intra-osseous umbilical cord blood ( UCB ) hematopoietic stem cell human mesenchymal stromal cell ( hMSC ) follow reduce intensity conditioning ( RIC ) . SECONDARY OBJECTIVES : I . To estimate time engraftment intra-osseous ( IO ) UCB transplant combine hMSC follow RIC . II . To estimate safety profile IO UBC transplant combine hMSC . OUTLINE : REDUCED INTENSITY CONDITIONING : Patients receive cyclophosphamide intravenously ( IV ) 2 hour day -6 fludarabine phosphate IV day -6 -2 undergo total body irradiation ( TBI ) day -1 . GRAFT-VERSUS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Patients receive cyclosporine orally ( PO ) IV 2 hour every 12 hour begin day -5 100 taper begin day 100 mycophenolate mofetil IV PO twice daily ( BID ) day -5 100 . TRANSPLANT : Patients undergo intra-osseous UCB hMSC co-transplant day 0 . After completion study treatment , patient follow day 28 100 , 6 , 9 , 12 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must one follow malignancy : Acute myelogenous leukemia ( AML ) : highrisk AML include : Antecedent hematological disease ( e.g. , myelodysplasia [ MDS ] ) Treatmentrelated leukemia Complete remission ( first complete remission [ CR1 ] ) poorrisk cytogenetics molecular marker ( e.g . fmsrelated tyrosine kinase 3 [ Flt 3 ] mutation , 11q23 , del 5 , del 7 , complex cytogenetics ) Second complete remission ( CR2 ) third complete remission ( CR3 ) Induction failure first relapse either ≤ 10 % blast marrow and/or ≤ 5 % blast peripheral blood Acute lymphoblastic leukemia ( ALL ) Highrisk CR1 include : Poorrisk cytogenetics ( e.g. , Philadelphia chromosome ( 9 ; 22 ) 11q23 rearrangement ) Presence minimal disease flow cytometry 2 cycle chemotherapy No complete remission ( CR ) within 4 week initial treatment Induction failure CR2 CR3 either : ≤ 10 % blast marrow and/or ≤ 5 % blast peripheral blood Induction failure Myelodysplastic syndrome ( MDS ) , Intermediate1 ( INT1 ) , intermediate2 ( INT2 ) high Revised International Prognostic Scoring System ( IPSSR ) score fail least 1 first line therapy Myelofibrosis ( MF ) : Intermediate2 high risk Dynamic International Prognostic Scoring System ( DIPSS ) plus Monosomal karyotype Presence inv ( 3 ) /i ( 17q ) abnormalities Other unfavorable karyotype OR leukocytes ≥40 X 10^9/L AND Circulating blast ≤ 9 % Relapsed refractory lymphoid malignancy ( include nonHodgkin lymphoma , Hodgkin lymphoma chronic lymphocytic leukemia ) meeting follow criterion : Disease status : stable disease , partial remission 2nd 3rd complete remission Chronic myelogenous leukemia ( CML ) second chronic phase accelerate blast crisis ; blast crisis define : Blast count ≥ 20 % peripheral blood bone marrow Large focus blast bone marrow Presence extramedullary blastic infiltrate ( myeloid sarcoma chloroma ) Recipients prior autologous allogeneic transplant eligible , long least 3 month pass since transplant , patient fulfills eligibility criterion Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Candidates reduce intensity conditioning regimens Patients human leukocyte antigen ( HLA ) match ( define match HLA A , B , C , DRB1 ) relate unrelated donor Cord Blood Units available NMDP follow minimal criterion : HLA Match : 4/6 good match ( HLA A , B , DRB1 ) Cell dose : Minimum 2x107TNC/kg pre thaw Concurrent therapy extramedullary leukemia central nervous system ( CNS ) lymphoma : concurrent therapy prophylaxis testicular leukemia , CNS leukemia , CNS lymphoma include standard intrathecal chemotherapy and/or radiation therapy allow clinically indicate ; treatment may continue planned course complete ; subject must CNS remission time protocol enrollment history CNS involvement Subjects must backup umbilical cord registry addition umbilical cord use study Subjects must ability understand willingness sign write informed consent document Patients inadequate Organ Function define : Creatinine clearance &lt; 30 ml/min Bilirubin ≥ 2 x institutional upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) ≥ 2 x institutional upper limit normal Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) ≥ 2 x institutional upper limit normal Corrected diffusing capacity lung carbon monoxide ( DLCOcorr ) &lt; 40 % normal Left ventricular ejection fraction &lt; 35 % Patients uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed woman exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Total Body Irradiation</keyword>
	<keyword>Human Mesenchymal Stromal Cells</keyword>
	<keyword>hMSC</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Dimethyl Sulfoxide</keyword>
	<keyword>DMSO</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>Granulocyte- Colony Stimulating Factor</keyword>
	<keyword>G-CSF</keyword>
	<keyword>GVHD</keyword>
	<keyword>Cancer</keyword>
	<keyword>feasibility</keyword>
</DOC>